NMMRC OF RADIOLOGY EXPANDS RADIONUCLIDE DIAGNOSTICS CAPABILITIES

The Department of Radionuclide Therapy and Diagnostics at P. Hertsen Moscow Oncology Research Institute (MORI) for medical work – the branch of the FSBI “National Medical Research Radiological Centre” (NMRRC) of the Ministry of Health of the Russian Federation, has started performing PET/CT with [18F]PSMA-1007, which is an effective method for diagnosing prostate cancer at various stages of the disease.

️Prostate-specific membrane antigen or PSMA is a receptor first discovered specifically in prostate tissue, however, it is currently known that it also physiologically accumulates in other tissues of the human body. PSMA expression in tumor cells, especially prostate cancer, is 100-1000 times higher than the physiological level, which allows PSMA to be effectively used as a target for radionuclide diagnostics and therapy.

The main indications for PET/CT with [18F]PSMA-1007 are:

– Assessment of the prevalence of first diagnosed prostate cancer. The study is recommended for patients at high or unfavorable intermediate risk, as well as for equivocal results of conventional imaging techniques, regardless of risk group.